Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bivalirudin - Eagle Pharmaceuticals

Next Previous
Drug Profile

Bivalirudin - Eagle Pharmaceuticals

Alternative Names: Bivalirudin RTU; EP-6101; Kangio; Ready-to-use bivalirudin; RTU bivalirudin

Latest Information Update: 12 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eagle Pharmaceuticals
  • Class Antithrombotics; Hirudins; Ischaemic heart disorder therapies; Peptide fragments; Recombinant proteins
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Heparin-induced thrombocytopenia and thrombosis syndrome; Unstable angina pectoris

Most Recent Events

  • 30 Jun 2017 Discontinued - Preregistration for Heparin-induced thrombocytopenia and thrombosis syndrome in USA (IV)
  • 30 Jun 2017 Discontinued - Preregistration for Unstable angina pectoris in USA (IV)
  • 15 Mar 2017 Eagle pharmaceuticals and The Medicines company has patent protection for bivalirudin in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top